Fact-checked by Grok 2 weeks ago

Neurotechnology

Neurotechnology encompasses technologies and methods that interface directly with the nervous system to monitor, record, stimulate, or modulate neural activity, enabling insights into brain function or alterations to nervous system processes.^[1]^[2] These include brain-computer interfaces (BCIs), neural prosthetics, deep brain stimulation (DBS), and noninvasive techniques such as transcranial magnetic stimulation (TMS).^[3] Key applications span medical therapeutics, where neurotechnologies treat conditions like Parkinson's disease through DBS implants that alleviate motor symptoms by modulating basal ganglia activity, and assistive devices that restore function in paralysis via BCIs decoding neural signals for cursor control or communication.^[4] Notable achievements include FDA-approved BCIs enabling quadriplegic individuals to achieve speech synthesis rates approaching conversational speeds and prosthetic limbs providing sensory feedback, demonstrating causal efficacy in restoring lost capabilities grounded in neural signal processing.^[5] Recent advances, such as high-density electrode arrays and AI-integrated decoding algorithms, have expanded precision in neural interfacing, with clinical trials showing sustained motor recovery in spinal cord injury patients.^[6] Despite these empirical benefits, neurotechnology raises ethical controversies centered on neuroprivacy—the protection of neural data from unauthorized access or manipulation—and informed consent challenges in closed-loop systems that adaptively alter brain states.^[7]^[8] Concerns include potential misuse for cognitive enhancement exacerbating social inequalities, risks of hacking implantable devices, and the blurring of therapeutic versus non-therapeutic boundaries, prompting calls for regulatory frameworks prioritizing causal risks over speculative fears while acknowledging biases in academic discourse that may underemphasize individual autonomy in favor of collective safeguards.^[9]^[10]

Definition and Scope

Core Principles and Technologies

Neurotechnology relies on the biophysical foundations of neural electrophysiology, where neurons generate action potentials through rapid ion channel-mediated depolarization and repolarization, producing extracellular electric fields measurable in microvolts. These signals, arising from synchronized activity of neuronal ensembles, enable technologies to record, decode, or modulate brain function by interfacing with the nervous system's inherent electrical conductivity and volume conduction properties.^[11] Fundamental to this is the detection of local field potentials (LFPs) from synaptic currents or spike potentials from axonal firing, which propagate at velocities up to 120 m/s in myelinated fibers, allowing temporal resolution down to milliseconds in high-fidelity recordings.^[12] Core recording technologies span invasive and non-invasive modalities. Invasive approaches, such as intracortical microelectrode arrays (e.g., the 96-channel Utah array in BrainGate systems), penetrate cortical tissue to isolate single-neuron spiking with bandwidths exceeding 1 kHz and signal-to-noise ratios optimized via impedance matching below 1 MΩ at 1 kHz.^[13] These enable precise mapping of motor intent, as demonstrated in human trials where implanted arrays facilitated control of robotic arms with up to 7 degrees of freedom.^[13] Semi-invasive electrocorticography (ECoG) deploys electrode grids on the brain surface for mesoscale LFPs with less tissue damage than penetration. Non-invasive methods include electroencephalography (EEG), utilizing scalp electrodes to capture broadband cortical oscillations (0.5-100 Hz) from summed postsynaptic potentials, though limited by skull attenuation reducing amplitudes to 10-100 μV.^[14] Magnetoencephalography (MEG) detects magnetic fields from tangential currents with femtotesla sensitivity, offering superior localization without conductivity distortions.^[11] Stimulation principles exploit the same ionic mechanisms in reverse, delivering targeted currents to evoke action potentials at thresholds of 10-100 μA for microelectrodes, altering membrane potentials via capacitive coupling or direct charge injection.^[13] Invasive deep brain stimulation (DBS) electrodes, implanted since FDA approval in 1997 for Parkinson's, deliver biphasic pulses at 1-200 Hz to disrupt pathological oscillations, with over 150,000 devices implanted globally by 2020.^[14] Non-invasive transcranial magnetic stimulation (TMS) induces eddy currents via time-varying magnetic fields (1-2 T peak), focally depolarizing neurons at depths up to 2 cm, while transcranial direct current stimulation (tDCS) applies weak fields (1-2 mA) to subthreshold modulate excitability over 20-30 minutes.^[14] Functional magnetic resonance imaging (fMRI), though primarily recording hemodynamic responses via blood-oxygen-level-dependent (BOLD) contrasts with 1-3 second latency, informs closed-loop systems by correlating vascular changes to neural metabolism.^[11] Data processing underpins usability, involving analog-to-digital conversion at 20-40 kHz sampling rates, artifact rejection via independent component analysis, and decoding via linear models or neural networks to translate signals into commands, achieving accuracies over 90% in cursor control tasks for invasive BCIs.^[13] These principles integrate hardware biocompatibility—using materials like platinum-iridium for chronic stability—and software for real-time feedback, enabling bidirectional interfaces that both sense and actuate neural circuits.^[13]

Distinctions from Neuroscience and Biotechnology

Neurotechnology is differentiated from neuroscience by its applied engineering focus rather than pure scientific investigation. Neuroscience constitutes the multidisciplinary study of the nervous system's anatomy, physiology, biochemistry, genetics, and cognitive functions, seeking to uncover underlying biological principles through experimental methods like imaging, electrophysiology, and behavioral assays.^[3] In contrast, neurotechnology develops hardware and software systems—such as electrodes, sensors, and algorithms—that enable direct interaction with neural circuits to record activity, deliver stimuli, or decode intentions, prioritizing functional outcomes like motor restoration in paralysis patients over explanatory models.^[1] This technological orientation often draws on neuroscience findings but extends into device fabrication, signal processing, and biocompatibility challenges, as seen in brain-computer interfaces (BCIs) that translate neural spikes into cursor control with latencies under 100 milliseconds.^[2] While overlapping with biotechnology in therapeutic goals, neurotechnology emphasizes cybernetic and electronic interfaces over biological manipulation. Biotechnology harnesses cellular, molecular, or organismal processes—via techniques like recombinant DNA, CRISPR editing, or bioreactor culturing—to engineer products such as vaccines or enzymes, frequently targeting systemic or non-neural biology.^[15] Neurotechnology, however, centers on hybrid systems integrating synthetic materials with neural tissue, exemplified by Utah arrays with 96-128 microelectrodes penetrating cortex to achieve single-unit recordings exceeding 100 neurons simultaneously, distinct from biotech's reliance on endogenous cellular mechanisms like gene therapy vectors.^[16] This boundary is evident in applications: biotechnological neural interventions might involve optogenetic proteins expressed via adeno-associated viruses to modulate genetically targeted neurons, whereas neurotechnologies deploy inert implants or transcranial magnetic coils for millisecond-precision stimulation without genetic alteration.^[2] Such distinctions underscore neurotechnology's foundation in electrical engineering and materials science, reducing dependence on living biological substrates.

Historical Development

Pre-Modern Foundations and Early Experiments

The earliest recorded applications of neurostimulation trace back to ancient civilizations, where electric fish such as the torpedo ray (Torpedo species) were employed for therapeutic purposes, including pain relief and seizure treatment, as documented by Pliny the Elder in the 1st century AD and Galen in the 2nd century AD.^[17] These practices leveraged the fish's natural electric discharge to induce numbness or muscle contractions, prefiguring modern electrical neuromodulation without an understanding of underlying neural mechanisms.^[17] In the late 18th century, foundational insights into bioelectricity emerged through Luigi Galvani's experiments, beginning in 1786, which demonstrated that electrical stimulation of frog sciatic nerves and muscles could elicit contractions independently of external sources, leading to his 1791 publication positing "animal electricity" as an intrinsic neural property.^[18] This challenged prevailing vitalist views and established the electrical nature of nerve impulses, though debates with Alessandro Volta—who in 1800 developed the voltaic pile battery partly in response—highlighted tensions between biological and artificial electricity.^[18] Galvani's work laid empirical groundwork for recognizing neural signals as electrochemical phenomena, influencing subsequent neurophysiological research.^[19] The 19th century advanced these foundations with quantitative measurements of neural activity. In the 1840s, Emil du Bois-Reymond pioneered the recording of action potentials from human and animal nerves using multiplier electrodes, confirming electrical currents in living tissue and quantifying their decay over distance.^[20] Concurrently, Hermann von Helmholtz measured nerve conduction velocity at approximately 61 meters per second in frog sciatic nerves in 1850, providing the first numerical evidence of signal propagation speed.^[21] These experiments shifted neurotechnology toward instrumentation for signal detection, enabling rudimentary interfaces between biological nerves and external detectors. Early direct brain stimulation experiments culminated in the 1870 work of Gustav Fritsch and Eduard Hitzig, who applied galvanic currents to the exposed cortex of anesthetized dogs, eliciting contralateral limb movements and mapping motor areas in the frontal gyrus—demonstrating localized excitability without phrenological assumptions.^[20] Building on this, in 1883, Alberto Alberti conducted prolonged cortical stimulation in a dog over eight months using zinc electrodes, observing behavioral modifications and tissue reactions, which foreshadowed chronic implantation challenges.^[22] These pre-20th-century efforts, though limited by crude tools and ethical constraints, established causal links between electrical inputs and neural outputs, forming the empirical basis for later neurotechnological interfaces.^[20]

20th-Century Milestones in Stimulation and Recording

In 1924, German psychiatrist Hans Berger achieved the first recording of human brain electrical activity via electroencephalography (EEG), using scalp electrodes to detect rhythmic oscillations correlated with mental states.^[23] This non-invasive technique laid foundational methods for monitoring cortical activity, later replicated and expanded by Edgar Adrian in the 1930s to identify alpha waves and their modulation by sensory input.^[24] Berger's work, initially met with skepticism due to rudimentary amplification technology, enabled subsequent quantitative analyses of brain rhythms in clinical settings like epilepsy diagnosis.^[25] During the 1930s and 1940s, neurosurgeon Wilder Penfield pioneered direct electrical stimulation of the exposed human cortex in awake patients undergoing epilepsy surgery at the Montreal Neurological Institute, mapping sensory, motor, and experiential functions to create the cortical homunculus.^[26] Penfield's intraoperative technique, involving low-voltage pulses from bipolar electrodes, elicited localized responses such as limb movements or sensory perceptions, confirming functional localization without permanent lesions and influencing stereotactic approaches.^[27] This method demonstrated precise causal links between stimulated sites and evoked phenomena, including rare hallucinatory recalls, though interpretations of memory activation remain debated for potential confounds like afterdischarges.^[28] Advancements in microelectrode technology enabled single-unit recordings by the mid-1950s, with initial human intracortical captures during neurosurgical procedures revealing action potentials from individual neurons.^[29] In 1952, Alan Hodgkin and Andrew Huxley recorded transmembrane currents in squid giant axons, deriving the first quantitative model of action potential propagation via voltage-clamp methods, which generalized to mammalian neural signaling.^[30] These intracellular techniques, refined through glass micropipettes, quantified ionic conductances underlying excitability, providing biophysical foundations for interpreting extracellular spikes.^[31] In the 1960s, José Delgado advanced implantable stimulation with the "stimoceiver," a radio-telemetered device allowing remote activation of chronic depth electrodes in animal and human subjects, notably halting a charging bull via basal ganglia stimulation in 1963.^[32] This demonstrated wireless control over aggressive behaviors, though ethical concerns arose from potential overrides of volition.^[33] Concurrently, stereotactic deep brain stimulation emerged mid-century, shifting from ablative procedures to reversible thalamic and pallidal targeting for movement disorders like Parkinson's, using modified pacemakers for chronic delivery.^[34] Early applications in the 1940s–1960s for psychiatric conditions, such as septal stimulation for mood elevation, highlighted neuromodulation's therapeutic potential but underscored risks of unintended psychological effects.^[35] By the late 20th century, these techniques converged in hybrid systems for recording and stimulating subcortical structures, paving empirical grounds for closed-loop neuroprosthetics.^[24]

21st-Century Acceleration and BCI Emergence

The 21st century witnessed accelerated development in neurotechnology, particularly brain-computer interfaces (BCIs), fueled by advances in microelectrode arrays, machine learning for signal decoding, and substantial public-private funding. Early milestones included the launch of the BrainGate pilot clinical trial in 2004, which implanted a 96-channel Utah array in a patient with tetraplegia, allowing decoding of motor cortex signals to control a computer cursor via imagined movements.^[36] By 2006, BrainGate participants achieved thought-based control of cursors, email composition, and robotic arms, demonstrating practical utility for restoring communication and mobility in paralyzed individuals.^[37] These invasive BCIs built on prior animal studies, with human trials expanding through the 2010s amid thousands of research publications reflecting heightened academic and clinical interest.^[38] Government initiatives further propelled BCI progress, notably DARPA's Neural Engineering System Design (NESD) program, initiated around 2016, which targeted high-resolution interfaces capable of reading signals from up to one million neurons and stimulating 100,000 for applications in sensory restoration.^[39] Complementing this, DARPA's Next-Generation Nonsurgical Neurotechnology (N3) program, launched in 2018, sought non-invasive, bi-directional BCIs using acoustics, optics, or electromagnetics to achieve sub-millimeter precision in reading and writing to neural tissue without surgery, aiming to enhance military multitasking and unmanned system control.^[40] These efforts addressed longstanding challenges like signal fidelity and biocompatibility, while fostering innovations in wireless telemetry and chronic implantation stability. Private sector involvement surged in the mid-2010s, exemplified by Neuralink's founding in 2016 to create scalable, high-channel-count BCIs with flexible threads for minimal tissue damage.^[41] Neuralink received FDA breakthrough device designation in 2020 and conducted its first human implantation in January 2024, enabling a quadriplegic patient to control a computer cursor and play games through neural activity.^[42] Concurrently, investments in neurotechnology reached record levels in 2024, with billions directed toward BCI firms, projecting market growth from $1.16 billion in 2025 to substantial expansion driven by clinical trials for paralysis, stroke rehabilitation, and beyond.^[43] Approximately 25 BCI implant trials were underway by 2025, signaling a shift from experimental prototypes to viable therapeutic and augmentation tools.^[44]

Scientific Foundations

Neural Signal Mechanisms

Neural signals in the brain arise from the biophysical properties of neurons, which generate and propagate electrical impulses known as action potentials. These are transient, self-regenerating depolarizations of the neuronal membrane, typically lasting 1-2 milliseconds, initiated when excitatory inputs summate to reach a threshold potential of approximately -55 mV from a resting state of -65 to -70 mV.^[45] The mechanism relies on voltage-gated ion channels: rapid opening of sodium channels permits Na⁺ influx, driving depolarization to +30 to +40 mV, followed by sodium channel inactivation and delayed potassium channel activation, which effluxes K⁺ to repolarize and hyperpolarize the membrane.^[46] This process, first quantitatively modeled by Alan Hodgkin and Andrew Huxley in 1952 using voltage-clamp experiments on squid giant axons, demonstrates how action potentials maintain amplitude and speed (up to 100 m/s in myelinated fibers) during propagation along axons due to sequential channel activation.^[46] Myelin sheaths, formed by oligodendrocytes or Schwann cells, enhance conduction velocity via saltatory propagation, where action potentials "jump" between nodes of Ranvier rich in these channels.^[45] At synaptic terminals, arriving action potentials trigger calcium influx through voltage-gated Ca²⁺ channels, prompting vesicular release of neurotransmitters such as glutamate (excitatory) or GABA (inhibitory) into the synaptic cleft within 1 millisecond.^[47] These molecules diffuse across the 20-40 nm cleft to bind postsynaptic receptors, generating excitatory postsynaptic potentials (EPSPs) via cation influx (e.g., AMPA receptors) or inhibitory postsynaptic potentials (IPSPs) via Cl⁻ or K⁺ fluxes, which summate spatially and temporally to influence whether the postsynaptic neuron fires.^[48] Electrical synapses, mediated by gap junctions allowing direct ion flow, enable faster (sub-millisecond) bidirectional transmission but are less common in mammalian brains than chemical synapses. Quantal release follows probabilistic rules, with each vesicle releasing ~5000-10000 molecules, ensuring reliable yet stochastic signaling.^[48] In neural ensembles relevant to neurotechnology, individual action potentials contribute to emergent signals like local field potentials (LFPs), which reflect synchronized synaptic currents from thousands of neurons within 100-500 μm, and multi-unit activity detectable extracellularly.^[45] Spike timing and firing rates (typically 0.1-100 Hz) encode information, with cortical neurons often exhibiting sparse, precise bursts; for instance, motor cortex pyramidal cells fire at 10-50 Hz during movement tasks.^[46] These mechanisms underpin decoding in brain-computer interfaces, where extracellular electrodes capture spike waveforms (50-300 μV amplitude, 0.5-2 ms duration) to infer intent, though signal-to-noise challenges arise from glial encapsulation and tissue impedance.^[45] Disruptions, such as channelopathies in epilepsy, highlight the precision of these ion dynamics for normal function.

Interface Engineering and Data Processing

Interface engineering in neurotechnology focuses on developing hardware that bridges electronic devices with neural tissue to enable reliable recording and stimulation of neural activity. Key challenges include minimizing tissue damage, ensuring long-term stability, and maximizing signal fidelity, as rigid implants like silicon-based Utah arrays provoke glial scarring and signal attenuation within months of implantation.^[49] Flexible materials, such as polyimide or hydrogels, reduce mechanical mismatch with brain tissue, improving biocompatibility by lowering inflammatory responses; for instance, hydrogel coatings on electrodes have demonstrated reduced gliosis in rodent models over 6 months.^[50] Electrode materials traditionally include platinum-iridium alloys for their high charge injection capacity, but emerging carbon nanotube or graphene composites offer higher impedance stability and lower toxicity.^[51] Biocompatibility strategies emphasize surface modifications to mitigate foreign body reactions, which involve protein adsorption followed by macrophage activation and fibrous encapsulation. Conductive polymers like PEDOT doped with PSS enhance electrode-tissue coupling by increasing effective surface area and reducing impedance to below 100 kΩ at 1 kHz, as measured in chronic primate implants.^[52] Designs such as microwire arrays, with diameters under 20 μm, allow for multi-site recording from hundreds of neurons, while advances in microfabrication enable high-density arrays exceeding 1000 channels, as in systems recording up to 10,000 neurons simultaneously in non-human primates.^[53] Wireless integration, using miniaturized CMOS chips, eliminates tethering artifacts and supports ambulatory recording, with power consumption below 10 μW per channel.^[54] Data processing pipelines transform raw neural signals into actionable outputs, beginning with acquisition via low-noise amplifiers (noise floors <5 μV rms) and analog-to-digital conversion at sampling rates of 20-30 kHz for action potentials. Preprocessing includes bandpass filtering (300-7000 Hz for spikes) and common average referencing to reject common-mode noise, reducing artifacts from motion or electromagnetic interference by up to 90%.^[55] Feature extraction identifies discriminative patterns, such as spike waveforms for invasive BCIs or event-related potentials for EEG, using techniques like principal component analysis to achieve signal-to-noise ratios above 10 dB.^[56] Decoding algorithms employ machine learning for intent prediction, with linear decoders like Kalman filters estimating cursor velocity from multi-unit activity in real-time latencies under 100 ms, enabling control accuracies exceeding 90% in human trials.^[57] Deep neural networks, including recurrent and convolutional architectures, have improved decoding of complex behaviors, such as speech from electrocorticographic signals, with word error rates below 25% in paralyzed patients.^[58] Adaptive methods, such as transfer learning, compensate for signal non-stationarity over weeks, maintaining performance despite electrode drift of 10-20% in impedance.^[59] Closed-loop systems integrate feedback, adjusting stimulation based on processed signals to enhance plasticity, as in deep brain stimulation paradigms reducing tremor by 70% via proportional-integral control.^[60]

Categories of Neurotechnologies

Invasive Approaches

Invasive neurotechnologies involve the surgical implantation of electrodes or microelectrode arrays directly into the brain or spinal cord to record neural signals or deliver electrical stimulation with high spatiotemporal resolution.^[61] These methods enable precise interfacing with individual neurons or small ensembles, yielding signal-to-noise ratios far superior to non-invasive techniques, which are limited by skull and tissue attenuation.^[62] Applications primarily target motor restoration in paralysis, symptom alleviation in movement disorders, and emerging brain-computer interfaces (BCIs) for communication and control.^[61] A prominent example is deep brain stimulation (DBS), where electrodes are implanted into subcortical structures such as the subthalamic nucleus or globus pallidus to modulate pathological activity. FDA-approved for Parkinson's disease and essential tremor since 1997 and 1999, respectively, DBS reduces motor impairment by approximately 53% after two years in patients, compared to 4% improvement with medication alone.^[63] Meta-analyses confirm DBS outperforms best medical therapy in improving disability and quality of life while allowing medication dose reductions, though benefits diminish in severe cases.^[64] Risks include hemorrhage (1-3%), infection (2-4%), and hardware complications like lead migration, necessitating careful patient selection.^[65]^[66] Intracortical microelectrode arrays, such as the Utah array developed at the University of Utah, penetrate the cortical surface to record extracellular action potentials from dozens to hundreds of neurons simultaneously.^[67] Deployed in systems like BrainGate, these arrays have enabled tetraplegic patients to control cursors, robotic arms, and text via decoded neural intent, with implants demonstrating functionality for up to eight years in clinical trials.^[68] Recent data from chronic human implants show average spiking yield on 35.6% of electrodes, with minimal decline over multi-year periods despite foreign body responses like gliosis.^[69]^[70] Advanced variants include Neuralink's N1 implant, featuring flexible polymer threads with over 1,000 electrodes inserted robotically into the motor cortex to minimize tissue damage. As of mid-2025, five paralyzed individuals used the device to operate computers and assistive robotics solely through thought, with ongoing feasibility trials expanding to external arm control.^[71]^[72] These systems face persistent challenges, including chronic signal degradation from astrocytic encapsulation and mechanical mismatch between rigid probes and soft tissue, which histological analyses reveal as localized inflammation and neuronal loss around implant sites.^[73]^[70] Despite such limitations, invasive approaches continue advancing through material innovations like ultraflexible polymers to enhance biocompatibility and longevity.^[74]

Non-Invasive Approaches

Non-invasive neurotechnologies interface with the brain through external means, avoiding surgical penetration of the skull or tissue, thereby reducing risks such as infection or tissue damage associated with invasive methods.^[75] These approaches encompass techniques for recording neural activity, such as electroencephalography (EEG) and functional magnetic resonance imaging (fMRI), and for stimulation, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). While offering greater safety and accessibility for clinical and research use, non-invasive methods generally provide lower spatial resolution and signal-to-noise ratios compared to invasive counterparts, limiting their precision in deep brain targeting or high-fidelity decoding. Advantages include portability for some devices, like EEG caps, enabling real-world applications in brain-computer interfaces (BCIs).^[76] EEG records electrical potentials generated by synchronized neuronal activity on the scalp, capturing signals from large populations of neurons with temporal resolutions in milliseconds.^[77] First demonstrated by Hans Berger in 1924, EEG has evolved into a cornerstone for non-invasive BCIs, facilitating applications in motor imagery decoding for paralyzed patients and seizure detection in epilepsy diagnostics.^[76] Wireless EEG systems, advanced since the 2010s, support ambulatory monitoring, though artifacts from muscle movement and poor spatial resolution (typically centimeters) constrain its utility for fine-grained localization.^[76] In neurotechnology, EEG-based BCIs have achieved accuracies up to 80-90% for binary tasks like left-right hand imagination in controlled settings, but performance drops in real-world scenarios due to signal variability.^[78] TMS employs rapidly changing magnetic fields to induce focal electrical currents in cortical neurons, with pulses penetrating 1-2 cm into the brain.^[79] Developed in 1985 by Barker et al., repetitive TMS (rTMS) received FDA approval in 2008 for treatment-resistant major depression, showing response rates of approximately 30-50% in meta-analyses, outperforming sham stimulation.^[79]^[80] Efficacy stems from modulating excitability in prefrontal regions, with protocols like intermittent theta-burst stimulation accelerating effects to minutes.^[81] Limitations include transient side effects like headaches and the need for multiple sessions, alongside inconsistent outcomes for non-depressive disorders such as schizophrenia.^[81] tDCS applies weak direct currents (1-2 mA) via scalp electrodes to subtly shift neuronal membrane potentials, promoting or inhibiting excitability depending on polarity.^[82] Emerging in the 2000s from earlier electrical stimulation research, tDCS devices are portable and low-cost, with meta-analyses indicating modest antidepressant effects in major depression, particularly when combined with pharmacotherapy, yielding standardized mean differences of -0.73 for symptom reduction.^[83]^[84] However, evidence for cognitive enhancement in healthy individuals remains unsubstantiated, with quantitative reviews finding no reliable effects across studies.^[85] Variability arises from factors like electrode montage and individual anatomy, and long-term safety data are limited, though acute risks are minimal.^[86] fMRI indirectly measures neural activity via blood-oxygen-level-dependent (BOLD) signals, offering millimeter spatial resolution for mapping brain function but suffering from seconds-long temporal delays and non-portability.^[87] In BCIs, fMRI enables thought-based control, such as spatial navigation paradigms with accuracies around 70%, yet high costs (equipment exceeding hundreds of thousands of dollars) and scanner confinement restrict it to laboratory settings.^[87]^[88] Emerging hybrids, like ultrasound-integrated BCIs, aim to address resolution gaps by focusing acoustic waves non-invasively, showing promise in enhancing decoding precision as of 2024.^[89] Overall, non-invasive approaches prioritize ethical accessibility but require algorithmic advances, such as machine learning for signal processing, to overcome inherent biophysical constraints.^[90]

Pharmacological and Adjunctive Methods

Pharmacological methods in neurotechnology encompass chemical interventions that modulate neural activity through targeted drug-receptor interactions, often enabling precise control over specific neuronal populations without physical implants. Chemogenetics represents a prominent example, utilizing engineered G protein-coupled receptors, such as designer receptors exclusively activated by designer drugs (DREADDs), which respond only to inert ligands like clozapine-N-oxide rather than endogenous neurotransmitters.^[91] These systems allow systemic drug administration to activate or inhibit genetically targeted cells, facilitating reversible neuromodulation in behaving animals and potential translational applications in humans.^[92] First described in the early 2000s, chemogenetic tools have advanced to include variants for excitatory, inhibitory, or signaling-specific effects, with over 1,000 publications by 2023 demonstrating their utility in dissecting neural circuits underlying behavior, addiction, and psychiatric disorders.^[93] Adjunctive pharmacological approaches integrate drugs with other neurotechnologies to amplify therapeutic outcomes, particularly by enhancing neuroplasticity induced by non-invasive brain stimulation (NIBS) techniques like transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS). For instance, pharmacological agents targeting ion channels (e.g., calcium channel blockers) or neurotransmitter systems (e.g., GABAergic or glutamatergic modulators) can potentiate long-term potentiation (LTP)-like effects from NIBS, extending plasticity windows beyond stimulation sessions.^[94] Clinical trials have shown that adjunctive D-cycloserine, an NMDA receptor partial agonist, augments the antidepressant efficacy of intermittent theta-burst stimulation in major depressive disorder, with response rates improving from 40% to over 60% in randomized studies conducted through 2022.^[95] Similarly, combining NIBS with dopaminergic or cholinergic drugs optimizes recovery in neurological conditions, as evidenced by enhanced motor learning in stroke rehabilitation protocols where pharmaceutical co-administration increased cortical excitability by 20-30% compared to stimulation alone.^[96] Emerging hybrid methods further blur lines between pharmacological and device-based neurotechnologies, such as sono-chemogenetics, which employs focused ultrasound to transiently open the blood-brain barrier for deeper drug delivery to DREADD-expressing neurons, achieving targeted modulation at depths up to 9 mm in rodent models as of 2025.^[97] Quantitative systems pharmacology models integrate these interactions, simulating drug dynamics on neural networks to predict efficacy and minimize off-target effects, with applications in modeling antipsychotics' impact on dopamine pathways.^[98] Despite promise, challenges persist, including ligand specificity, immune responses to viral vectors for receptor delivery, and limited human translation due to genetic modification requirements; ongoing research prioritizes non-viral delivery and endogenous receptor engineering to address these.^[99]

Applications

Medical and Therapeutic Uses

Neurotechnologies encompass neuromodulation techniques, brain-computer interfaces (BCIs), and neural prosthetics applied to treat neurological disorders, restore lost functions, and alleviate symptoms unresponsive to pharmacological interventions. Deep brain stimulation (DBS) delivers electrical pulses via implanted electrodes to targeted brain nuclei, proving effective for movement disorders like Parkinson's disease (PD), where it reduces motor fluctuations and dyskinesias by 40-60% compared to optimal medical therapy alone in randomized trials.^[100] A 2024 systematic review of 25 studies involving over 1,200 PD patients confirmed DBS improves Unified Parkinson's Disease Rating Scale motor scores by approximately 50% off-medication, though with risks including infection (3-5%) and hemorrhage (1-2%).^[101] DBS received FDA approval for essential tremor in 1997 and PD in 2002, with adaptive variants showing sustained benefits in long-term trials up to five years.^[102]^[103] For epilepsy, responsive neurostimulation systems, FDA-approved since 2013, detect and interrupt seizures via closed-loop DBS-like mechanisms, reducing seizure frequency by over 50% in 60% of refractory patients after two years.^[104] Vagus nerve stimulation (VNS), approved in 1997, modulates brainstem activity to decrease seizures by 20-40% on average, with higher efficacy in pediatric cases.^[102] In psychiatric applications, DBS targets circuits in treatment-resistant depression and obsessive-compulsive disorder (OCD), yielding response rates of 40-60% in open-label studies, though randomized evidence remains limited due to ethical challenges in sham controls.^[4] BCIs translate neural signals into commands for external devices, enabling communication and control for individuals with severe paralysis from amyotrophic lateral sclerosis (ALS) or spinal cord injury. Invasive electrocorticography-based systems, such as those trialed in BrainGate, allow cursor operation and text generation at speeds up to 90 characters per minute with 90% accuracy in quadriplegic users.^[105] A 2016 fully implanted BCI restored yes/no communication for a locked-in ALS patient at home, functioning reliably for over a year.^[106] Recent decoder advancements in 2024 enabled a paralyzed individual to produce intelligible speech from brain activity at 78 words per minute, surpassing prior non-invasive rates.^[107] Neural prosthetics restore sensory input by bypassing damaged pathways. Cochlear implants, stimulating the auditory nerve directly, have been implanted in over 700,000 patients worldwide since FDA approval in 1984, providing open-set speech recognition in 80-90% of post-lingually deaf adults.^[104] For vision, retinal prostheses like Argus II, approved in 2013, elicit phosphenes for basic navigation in retinitis pigmentosa patients, though limited to low resolution (60 electrodes).^[102] Cortical visual prostheses, targeting the occipital cortex, show promise in trials for profound blindness, with 2025 reports of a subretinal implant (PRIMA) restoring form vision in macular degeneration via 378 electrodes.^[108]^[109] These devices leverage neural plasticity, with efficacy correlating to post-implantation training durations of 3-6 months.^[110]

Human Enhancement and Augmentation

Neurotechnologies for human enhancement seek to augment cognitive, sensory, perceptual, or motor capabilities in non-clinical populations, extending beyond restorative applications to elevate baseline human performance. Brain-computer interfaces (BCIs) represent a primary modality, enabling direct neural interfacing with external systems to facilitate rapid information processing, memory consolidation, or skill acquisition. For instance, high-bandwidth invasive BCIs, such as those developed by Neuralink, aim to integrate human cognition with artificial intelligence, potentially accelerating learning and problem-solving by providing instantaneous access to vast data repositories or computational aids.^[111]^[112] Empirical evidence for cognitive augmentation remains preliminary but includes demonstrations of memory enhancement via BCIs. A 2015 study utilized a BCI to detect pre-stimulus neural patterns predictive of successful episodic memory encoding, applying targeted neurofeedback to improve recall accuracy in healthy participants by modulating hippocampal activity. Similarly, non-invasive EEG-based BCIs have boosted memory performance by leveraging theta (4-8 Hz) and alpha (8-12 Hz) oscillations associated with encoding processes, with one analysis showing substantial gains in word-list retention tasks. These approaches exploit neuroplasticity, where closed-loop feedback reinforces synaptic strengthening, though long-term effects in healthy adults require further validation beyond short-term trials.^[113]^[114] Military applications underscore practical augmentation efforts, as evidenced by DARPA's Targeted Neuroplasticity Training (TNT) program, launched in 2017, which employs non-invasive neuromodulation to accelerate learning in service members by enhancing cholinergic signaling and synaptic plasticity during complex task training. The Next-Generation Nonsurgical Neurotechnology (N3) initiative, initiated in 2018, develops bidirectional interfaces capable of reading and writing to 16 neural channels within millimeters of tissue without implantation, targeting enhanced situational awareness or decision-making under stress. While these programs prioritize operational efficacy—such as faster skill acquisition for multifaceted tasks—their technologies could generalize to civilian contexts like professional training or creative output, albeit with scalability limited by signal fidelity and individual variability.^[115]^[40] Challenges in realization include biocompatibility for invasive systems and signal resolution for non-invasive ones, with current enhancements yielding modest gains (e.g., 10-20% improvements in memory tasks) rather than transformative leaps. Neuralink's first human implantation in January 2024 demonstrated cursor control via thought in a quadriplegic patient, laying groundwork for broader augmentation, but peer-reviewed data on healthy-subject enhancements are sparse, highlighting a gap between proprietary demonstrations and independently verified outcomes. Ongoing research emphasizes causal mechanisms, such as optogenetic or ultrasonic modulation to induce targeted plasticity, yet ethical deployment in non-therapeutic contexts demands rigorous assessment of durability and unintended neural alterations.^[116]^[112]

Military, Commercial, and Emerging Sectors

In the military domain, neurotechnologies are primarily developed to enhance operational capabilities, treat combat-related neurological injuries, and enable direct neural control of systems. The U.S. Defense Advanced Research Projects Agency (DARPA) has funded brain-computer interfaces (BCIs) since the 1970s, focusing on applications such as restoring memory function through implantable devices under the Restoring Active Memory (RAM) program, which targets hippocampal stimulation for service members with traumatic brain injuries.^[117]^[118] Noninvasive techniques, including transcranial direct current stimulation (tDCS), have been explored to improve focus, reduce training time, and mitigate stress in soldiers, as detailed in analyses of potential battlefield enhancements.^[119] DARPA's Next-Generation Nonsurgical Neurotechnology (N3) program, initiated to develop bidirectional, high-performance interfaces without surgery, aims to allow able-bodied personnel to interface with unmanned systems or prosthetics via neural signals, emphasizing portability and minimal invasiveness for field deployment.^[40] Similarly, the Systems-Based Neurotechnology for Emerging Therapies (SUBNETS) initiative seeks precise interventions for neuropsychiatric conditions prevalent in military contexts, such as PTSD, by modulating deep brain circuits.^[120] Commercial applications of neurotechnology center on medical devices for diagnostics and therapeutics, with expanding forays into consumer wellness products. Leading firms like Medtronic, Abbott Laboratories, and Boston Scientific dominate the market through neurostimulation devices for conditions like Parkinson's disease and chronic pain, contributing to a sector valued at approximately USD 15.3 billion in 2024.^[121]^[122] Projections indicate growth to USD 52.86 billion by 2034 at a compound annual growth rate (CAGR) of 13.19%, driven by advancements in implantable BCIs and electroencephalography (EEG) wearables.^[122] Consumer-oriented neurotech, comprising about 60% of global firms by mid-2025, integrates EEG with AI for applications in cognitive training, sleep optimization, and biofeedback, often marketed as non-medical tools for productivity enhancement despite limited empirical validation beyond basic neuromonitoring.^[123] Emerging sectors highlight hybrid and non-traditional uses, including AI-convergent interfaces and nanotechnology-enabled probes for real-time neural mapping. Trends as of 2025 include sensory feedback prosthetics that restore touch sensation via neural stimulation, advancing beyond motor control in BCIs for paralysis patients toward broader sensory augmentation.^[5] Convergence with artificial intelligence and nanomaterials is enabling nanoscale neural interfaces for precise drug delivery or optogenetic modulation, potentially expanding to non-clinical domains like virtual reality integration for training simulations.^[124] Digital brain modeling and AI-assisted neuroradiology are gaining traction for predictive analytics in cognitive decline, though scalability remains constrained by data privacy and computational demands.^[125] These developments, while promising empirical gains in precision interfacing, face hurdles in long-term biocompatibility and regulatory approval outside established medical pathways.^[126]

Recent Advancements

Implantable BCI Innovations

Implantable brain-computer interfaces (BCIs) represent a class of neurotechnologies involving surgical placement of electrodes directly into brain tissue to record and stimulate neural activity with high fidelity. Innovations in this domain have advanced electrode density, biocompatibility, and wireless transmission, enabling precise decoding of motor intentions and sensory feedback. For instance, systems now incorporate thousands of channels to capture fine-grained signals, surpassing earlier Utah arrays limited to around 100 electrodes.^[127] Neuralink's N1 implant, featuring 1,024 electrodes on flexible threads inserted via robotic surgery, achieved the first human implantation in January 2024 for a quadriplegic patient, who demonstrated cursor control on a computer screen through thought alone. By August 2024, a second participant received the device, reporting sustained functionality for digital interaction. In 2025 updates, Neuralink expanded trials, with participants achieving high-speed typing and plans for speech restoration trials targeting impairments like ALS. These developments leverage machine learning algorithms to translate neural spikes into actions, with reported bandwidth exceeding 10 bits per second in early users.^[128]^[112]^[72] Synchron's Stentrode device innovates by deploying electrodes endovascularly via the jugular vein into the superior sagittal sinus, avoiding craniotomy and reducing surgical risks. Implanted in multiple patients since FDA breakthrough designation in 2021, it enabled thought-controlled texting and web browsing in a 2025 trial, integrating with apps like WhatsApp. This minimally invasive approach has shown signal stability over years, with one patient using it for over 1,000 days without decline.^[129]^[130]^[131] BrainGate, utilizing Blackrock Neurotech's Utah array, has facilitated clinical milestones including a patient achieving 90 characters per minute typing via imagined handwriting in 2021 trials, with ongoing studies in 2025 demonstrating robotic arm control for grasping objects. Recent integrations include wireless prototypes tested in humans by the University of Michigan in June 2025, recording neural data without percutaneous connectors for improved mobility. These systems underscore progress in signal processing to mitigate gliosis and maintain chronic recording quality.^[132]^[133] Emerging trials, such as Stanford's implantable decoder for inner speech in August 2025, reconstruct attempted utterances from neural patterns in speech-impaired individuals, achieving word error rates below 25% in small cohorts. Collectively, these innovations prioritize scalability and safety, with electrode materials like polyimide and iridium oxide enhancing longevity beyond 5 years in preclinical models, though human data remains preliminary.^[134]^[44]

Non-Invasive and Hybrid Progress

Recent developments in non-invasive brain-computer interfaces (BCIs) have focused on enhancing signal quality and decoding accuracy through high-density electrode arrays and dry electrode technologies, enabling portable, home-based applications without surgical intervention. Electroencephalography (EEG)-based systems, for instance, have incorporated advanced signal processing and machine learning algorithms to mitigate noise and improve spatiotemporal resolution, achieving up to 92% accuracy in steady-state visually evoked potential (SSVEP) paradigms for wheelchair navigation control as demonstrated in 2023 studies.^[135] Similarly, functional near-infrared spectroscopy (fNIRS) has advanced for motor-task classification, offering complementary hemodynamic insights to electrical signals with improved wearable designs that support volitional control in rehabilitation settings.^[135] These non-invasive modalities provide broader spatial coverage compared to invasive alternatives, though they historically lag in precision; recent self-supervised deep-learning methods have narrowed this gap by enabling continuous decoding of neural activity from 2023 onward.^[136] In therapeutic contexts, non-invasive BCIs have shown measurable clinical gains, such as in stroke recovery where EEG-driven neurofeedback increased Fugl-Meyer Assessment of Upper Extremity (FMA-UE) scores by an average of 13.17 points across 296 patients in a 2024 meta-analysis, outperforming traditional therapy's 9.83-point gains.^[135] By mid-2025, EEG systems enabled real-time control of robotic hands via motor imagery and execution paradigms, allowing precise individual finger movements without implantation, as validated in human trials.^[58] Functional near-infrared spectroscopy advancements include high-density wearable arrays that boost BCI accuracy for cognitive and motor tasks, addressing prior limitations in portability and signal fidelity.^[137] Hybrid approaches, integrating multiple non-invasive modalities, have further elevated performance by fusing complementary signals to overcome individual technique weaknesses, such as EEG's susceptibility to artifacts or fNIRS's lower temporal resolution. EEG-electromyography (EMG) hybrids, for example, reached 88.89% classification accuracy in stroke rehabilitation protocols in 2023, enhancing upper-limb function through synchronized neural-muscular feedback.^[135] EEG-fNIRS combinations similarly improve intent detection and cognitive state monitoring, with applications in closed-loop systems for neurological disorders like Parkinson's, where multimodal integration supports personalized motor recovery as of 2025.^[138] These hybrids leverage artificial intelligence for data fusion, yielding robust outcomes in everyday scenarios while maintaining safety and accessibility advantages over purely invasive methods.^[139]

Global Market and Regulatory Updates

The global neurotechnology market reached an estimated USD 15.77 billion in 2025, driven primarily by demand for brain-computer interfaces (BCIs) in treating neurological disorders such as paralysis and epilepsy, alongside expansions into cognitive enhancement and non-medical applications.^[121] Projections forecast the market expanding to USD 29.74 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13.53%, fueled by technological breakthroughs in implantable and non-invasive devices, though tempered by high development costs and clinical trial durations.^[121] Alternative analyses peg the 2025 valuation slightly higher at USD 17.32 billion, with potential to hit USD 52.86 billion by 2034 at a 13.19% CAGR, attributing acceleration to integrations with AI and rising investments in Asia-Pacific regions.^[140] Leading firms have secured substantial funding to scale operations. Neuralink completed a USD 650 million Series E round in June 2025, aimed at broadening human trials for its wireless implantable BCI to restore motor function in patients with spinal cord injuries.^[141] Blackrock Neurotech received a USD 200 million majority stake from Tether in 2024, enabling launches like the Axon-R system in May 2025 for research-grade neural recording, while Synchron has amassed over USD 145 million total funding for its endovascular stent-based BCI, which has demonstrated speech decoding in trials.^[142]^[143] In China, venture funding for brain implant startups doubled from 2024 levels by September 2025, exceeding 1.1 billion yuan, positioning domestic players to challenge U.S. dominance amid geopolitical tech races.^[144] Regulatory frameworks remain fragmented, prioritizing safety amid rapid innovation. In the United States, the FDA classifies most implantable BCIs as Class III medical devices, mandating premarket approval (PMA) processes that emphasize long-term safety and efficacy data from controlled trials, as evidenced by approvals for investigational use by Neuralink, Synchron, and Precision Neuroscience.^[145]^[146] Precision Neuroscience gained FDA clearance for its Layer 7-T minimally invasive BCI in August 2025, supporting high-resolution cortical mapping for therapeutic applications.^[147] In the European Union, neurotechnology devices fall under the Medical Device Regulation (MDR), with ongoing advocacy in 2025 for streamlined authorization to expedite market entry without compromising risk assessments, particularly for hybrid invasive-non-invasive systems.^[148] Globally, bodies like the International Medical Device Regulators Forum are harmonizing standards, but disparities persist, with emerging markets like China accelerating approvals to foster local innovation.^[144]

Ethical and Philosophical Issues

Neural data generated by brain-computer interfaces (BCIs) and other neurotechnologies pose unique privacy risks due to their potential to reveal intimate cognitive processes, emotions, and intentions, far surpassing traditional biometric data in sensitivity. Unlike fingerprints or facial scans, neural signals can expose subconscious thoughts or preferences, enabling "mind reading" capabilities that erode mental privacy.^[149] ^[150] For instance, bidirectional BCIs like those developed by Neuralink collect and transmit raw neural activity, raising concerns over unauthorized access to this data, which could be exploited for surveillance or manipulation.^[112] Regulatory frameworks lag behind, with calls for "neurorights" to protect cognitive liberty, as existing data protection laws like GDPR inadequately address the non-volitional nature of brain signals.^[151] Security vulnerabilities in implantable neurodevices amplify these threats, as demonstrated by demonstrated exploits in deep-brain stimulators, which can be wirelessly hacked to alter stimulation parameters, potentially inducing seizures or erratic behavior.^[152] "Brainjacking"—unauthorized control of neural implants—could enable attackers to manipulate motor functions or extract proprietary thoughts, with simulations showing cyberattacks disrupting realistic neuronal networks and causing functional impairments.^[153] ^[154] Manufacturers have faced criticism for insufficient encryption and firmware updates, leaving devices susceptible post-implantation, especially in abandoned projects where support ceases, heightening long-term risks.^[155] Obtaining valid consent for neurotechnology use is complicated by incomplete risk disclosure, device irreversibility, and potential cognitive alterations that impair ongoing decision-making. Clinical trials often fail to fully convey surgical risks like infection, electrode migration, or scar tissue formation, which may necessitate explantation—a procedure requiring separate consent that patients can revoke at any time.^[156] ^[157] Ethical analyses emphasize that informed consent must account for value-laden outcomes, such as identity shifts from restored agency, yet institutional review boards (IRBs) struggle with these nuances in implantable BCIs.^[158] ^[159] Post-trial abandonment by developers further undermines initial consent, exposing users to unaddressed vulnerabilities without recourse, underscoring the need for mandatory long-term oversight.^[155]

Autonomy, Identity, and Agency

Neurotechnologies such as brain-computer interfaces (BCIs) and deep brain stimulation (DBS) have sparked debates regarding their impact on human autonomy, defined as the capacity for self-determination, agency as the ability to initiate and control actions, and personal identity as the continuity of one's sense of self. In therapeutic applications for paralysis, BCIs enable users to restore agency by translating neural signals into external actions, such as controlling cursors or generating speech. For instance, a 2017 study demonstrated that individuals with tetraplegia achieved communication rates of up to 8 bits per second using implanted BCIs, allowing independent interaction with devices previously inaccessible due to motor impairment.^[160] Similarly, recent advancements in 2025 have restored naturalistic speech in paralyzed patients through BCIs decoding inner speech patterns, enhancing communicative autonomy without altering core identity.^[161] However, closed-loop neurotechnologies, which adaptively respond to brain activity, raise concerns about subtle influences on agency, potentially introducing dependencies or algorithmic biases that mediate user decisions. A 2025 scoping review of clinical studies found ethical gaps in addressing such autonomy risks, with many trials failing to systematically evaluate long-term effects on self-governance despite theoretical vulnerabilities like data privacy breaches or external hacking.^[162] Empirical evidence of actual autonomy erosion remains sparse, as most documented cases involve therapeutic benefits outweighing risks, though qualitative user reports highlight variability in perceived control post-implantation.^[163] Regarding personal identity, DBS for conditions like Parkinson's disease has been associated with changes in mood, behavior, or personality in some patients, prompting questions about self-continuity. Surveys of researchers indicate widespread awareness of such postoperative shifts, with a majority reporting instances of altered emotional or behavioral states.^[164] Yet, systematic reviews challenge overstated narratives, finding limited empirical support for profound dispositional trait changes; for example, a 2021 analysis concluded that while transient effects occur, stable personality alterations are not consistently observed across cohorts.^[165] In BCIs, identity disruptions appear minimal, with users often describing restored function as reaffirming rather than fracturing their sense of self, though relational agency frameworks suggest that technological mediation could redefine embodied action over time.^[166] Overall, while philosophical concerns persist, causal evidence prioritizes net gains in agency for disabled users over speculative identity harms.

Enhancement Ethics: Empirical Benefits versus Speculative Harms

Neurotechnological enhancements, such as brain-computer interfaces (BCIs) and transcranial direct current stimulation (tDCS), offer empirically verifiable improvements in cognitive functions for healthy individuals, including enhanced working memory and attention. Meta-analyses of tDCS studies indicate statistically significant gains in working memory among healthy older adults when paired with cognitive training, with effect sizes demonstrating reliable augmentation beyond placebo.^[167] Similarly, anodal tDCS over the prefrontal cortex has boosted vigilance and target detection in operational tasks, yielding measurable performance uplifts in healthy operators.^[168] Invasive neurotechnologies provide further evidence of augmentation potential. Deep brain stimulation (DBS) targeting the entorhinal cortex improved spatial memory encoding in human subjects during navigation tasks, with stimulated trials showing superior recall compared to non-stimulated conditions.^[169] BCI systems like BrainGate enable paralyzed individuals to achieve point-and-click communication rates and accuracies approaching those of able-bodied users, with typing speeds up to 90 characters per minute in optimized sessions, suggesting scalable benefits for augmentation in non-clinical populations.^[160] These outcomes, derived from controlled trials, underscore causal links between neural intervention and functional gains, often exceeding baseline human variability without technology. Critics of enhancement frequently invoke speculative harms, such as erosion of personal authenticity, coerced use, or dystopian mind control, yet these lack empirical substantiation in deployed systems. While theoretical taxonomies outline potential psychological or social disruptions, no large-scale studies document widespread identity alteration or autonomy loss from current neurotechnologies.^[170] Real risks, including surgical complications or device malfunction, are empirically low—BrainGate trials report adverse event rates comparable to standard neural implants, with interim data from over 100 participant-years showing minimal serious incidents.^[171] Overemphasis on unverified societal harms risks premature regulatory overreach, potentially denying benefits like accelerated learning or productivity, as cautioned in analyses of speculative neuroethics deterring therapeutic progress.^[172] This disparity highlights a core ethical tension: enhancement's demonstrated capacity to extend human capabilities, rooted in replicable neural modulation effects, versus harms that, absent causal evidence, resemble precautionary extrapolations rather than observed phenomena. Prioritizing empirical data favors advancing safe, voluntary applications, with ongoing trials mitigating known risks through iterative safety protocols.^[173]

Societal Impacts and Controversies

Accessibility, Inequality, and Economic Effects

High costs associated with neurotechnology devices, particularly implantable brain-computer interfaces (BCIs), restrict accessibility primarily to participants in clinical trials or individuals with substantial financial resources. For instance, Neuralink's implant surgery is estimated at $10,500 for exams, parts, and labor, with insurer costs potentially reaching $40,000 per procedure.^[174]^[175] Similarly, other brain implants range from $30,000 to over $100,000, including associated medical care, limiting widespread adoption beyond specialized medical contexts.^[176] Geographic, social, political, and economic factors further exacerbate barriers, with advanced neurotechnologies often concentrated in high-income regions like North America, where the market was valued at $9.7 billion in 2024.^[177]^[178] These access constraints contribute to inequality by creating disparities in cognitive and physical enhancement capabilities between socioeconomic groups. Low affordability of write-in BCI devices may amplify differences in abilities, as those with means gain advantages in productivity or rehabilitation while others remain excluded.^[179] Socioeconomic status influences acceptance of BCIs, with lower-status individuals facing heightened barriers due to health, education, and support limitations.^[180] In global terms, existing technology access gaps are projected to persist in neurotechnology deployment, potentially deepening divides between developed and developing nations, where profound differences in availability could hinder equitable benefits.^[181] Economically, the neurotechnology sector is expanding rapidly, valued at approximately $17.32 billion in 2025 and forecasted to reach $52.86 billion by 2034, driven by advancements in brain-machine interfaces.^[140] This growth could enhance productivity through performance monitoring and augmentation in professional environments, potentially boosting output in sectors like healthcare and manufacturing.^[182] However, limited evidence exists on direct job displacement from neurotechnology alone, though integration with automation may indirectly affect labor markets by enabling more efficient human-machine collaboration, with risks of widening income inequality if benefits accrue disproportionately to skilled or affluent users.^[183] Initiatives to improve equitable access, such as targeted funding for neurotech in underserved populations, aim to mitigate these effects, but implementation remains nascent.^[184]

Regulatory Challenges and Innovation Barriers

Implantable neurotechnologies, such as brain-computer interfaces (BCIs), are classified by the U.S. Food and Drug Administration (FDA) as Class III medical devices, necessitating Premarket Approval (PMA) to demonstrate safety and effectiveness through rigorous scientific review.^[185] The PMA process typically requires extensive preclinical and clinical data, including long-term biocompatibility testing for neural implants, with standard review timelines targeting 180 days but often extending beyond due to iterative safety concerns.^[185] Associated costs average approximately $75 million per device, encompassing clinical trials and regulatory submissions, which disproportionately burden emerging neurotech firms relative to established pharmaceutical pathways.^[186] Key regulatory hurdles stem from the inherent risks of neural interfaces, including electrode migration, chronic tissue response, and potential for irreversible brain damage, demanding nonclinical testing protocols outlined in FDA guidance issued in May 2021 for implanted BCIs in paralysis patients.^[187] These requirements amplify scrutiny on device durability, such as battery longevity and wireless telemetry, where uncertainties in human implantation—evident in animal model failures—prompt repeated data requests and delays.^[188] For instance, in early 2023, the FDA rejected Neuralink's investigational device exemption for human trials, citing unresolved issues with surgical robotics, wire stability, and biocompatibility, despite prior animal demonstrations of functionality.^[189] Internationally, the European Union's Medical Device Regulation (MDR), effective since 2021, imposes stringent clinical evaluation and post-market surveillance for high-risk neurodevices, reclassifying many as Class III equivalents and requiring Notified Body certification, which has extended approval timelines to 2-3 years in some medtech cases.^[190] Non-invasive neurotech falls under looser general product safety rules but faces classification ambiguities under MDR Annex XVI, complicating hybrid innovations.^[191] Such frameworks, while aimed at mitigating empirical risks like infection or neural degradation, create harmonization gaps across jurisdictions, forcing developers into parallel compliance tracks. These regulations erect innovation barriers by escalating financial and temporal demands, with PMA-equivalent processes deterring venture capital for startups—neurotech funding dropped 20% in 2023 amid regulatory uncertainty—and shifting focus from iterative prototyping to bureaucratic navigation.^[192] Empirical evidence from medtech indicates that prolonged approvals correlate with reduced R&D investment in high-risk fields, potentially delaying therapies for conditions like ALS, where BCIs have shown preliminary efficacy in restoring communication.^[193] Proponents argue for adaptive pathways, such as FDA's Breakthrough Devices Program, to expedite review without compromising causal evidence of safety, yet implementation remains inconsistent for novel neural tech.^[194]

Misuse Risks and Geopolitical Concerns

Neurotechnology, particularly brain-computer interfaces (BCIs), presents significant misuse risks due to vulnerabilities in device security and data handling. Adversaries could exploit wireless connections to hack implantable or wearable systems, enabling unauthorized access to neural signals, which might allow manipulation of thoughts, induction of false perceptions, or extraction of sensitive cognitive data such as intentions or memories.^[195]^[196] For instance, researchers have demonstrated theoretical attack vectors like "brain tapping" or adversarial stimuli that could alter user behavior without detection, with potential irreversible neurological effects from sustained interference.^[197]^[198] These risks extend to commercial devices, where inadequate encryption could lead to mass breaches affecting millions if standardized protocols fail, compromising mental privacy and enabling coercion or blackmail via intercepted brain data.^[199]^[150] Beyond individual harms, neurotechnology's dual-use nature facilitates weaponization, where civilian advancements could be repurposed for military ends such as non-consensual cognitive disruption or enhanced soldier performance. Programs like DARPA's Next-Generation Nonsurgical Neurotechnology (N3), initiated in 2018, aim to develop interfaces for controlling unmanned systems or cyber defense via neural signals, illustrating how such tools could enable remote weapon operation by thought alone, raising concerns over unintended escalation in conflicts.^[40] Neuroweapons targeting brain functions—potentially inducing fear suppression, behavioral overrides, or physiological sabotage—have been explored in defense contexts, with ethical analyses warning of indiscriminate effects akin to chemical agents.^[200]^[201] Geopolitically, intensifying U.S.-China rivalry in neurotechnology amplifies these risks, as both nations invest heavily in BCI for military superiority. China has outlined a national roadmap, announced in August 2025 by seven government departments, targeting breakthroughs by 2027 and global leadership by 2030, including explicit military applications for enhanced cognition and interface control.^[202] In contrast, U.S. efforts, such as DARPA initiatives, emphasize defensive and operational uses but face criticism for lagging in explicit strategic articulation compared to China's integrated civilian-military approach.^[203] This competition could spur an arms race in "neuroshields" and offensive capabilities, destabilizing international security by blurring lines between enhancement and coercion, with calls for treaties to regulate thought-controlled weapons emerging from organizations like UNIDIR.^[204]^[205] Export controls and governance gaps exacerbate proliferation risks, as dual-use exports to adversarial states could enable asymmetric threats without adequate verification mechanisms.^[206]

References

[1]
Neurotechnologies: The Next Technology Frontier | IEEE Brain
Neurotechnology refers to any technology that provides greater insight into brain or nervous system activity, or affects brain or nervous system function.
[2]
Neurotechnology: Current Developments and Ethical Issues - PMC
Dec 13, 2017 · Neurotechnology is defined as the assembly of methods and instruments that enable a direct connection of technical components with the nervous ...
[3]
The Promise of Neurotechnology in Clinical Translational Science
Neurotechnology is broadly defined as a set of devices used to understand neural processes and applications that can potentially facilitate the brain's ability ...
[4]
The grand challenge at the frontiers of neurotechnology and its ... - NIH
Jan 2, 2024 · Neurotechnology has been approved and used in the management of neurological disorders for decades but there is now rapid development in the ...Missing: achievements | Show results with:achievements
[5]
A roundup of five recent neurotechnology trends - R&D World
Feb 5, 2025 · 5 neurotech trends to watch in 2025: From paralysis recovery to prosthetics that feel and beyond · 1. Brain-computer interfaces (BCIs) for motor ...
[6]
2024's Top Neurotech Innovations: Key Breakthroughs and What ...
Nov 30, 2024 · Medtronic solidified its position as a key player in neurotechnology through advancements in neurostimulation devices. The company enhanced ...
[7]
Ethics of neurotechnology - UNESCO
When neurotechnology collects our brain data, specific issues can arise. Mental activity is our most intimate part which no one else had access to until now.UNESCO, leaders and top... · Towards an International... · UNESCO appoints...
[8]
Ethical gaps in closed-loop neurotechnology: a scoping review
Aug 8, 2025 · Inadequate consideration of neuroprivacy poses a significant research ethics concern. Beyond simply ensuring that data is anonymized and stored ...Missing: controversies | Show results with:controversies
[9]
Ethical and Legal Challenges of Neurotech - DLA Piper
Mar 27, 2025 · BCIs also pose significant risks and ethical challenges, with concerns ranging from health and privacy issues to the potential for misuse and unequal access.
[10]
Ethical Challenges in the Commercialization of Neurotechnology
The seven ethical issues and principles explored in the target article (ie, privacy, responsibility, access, stigma, user control, family impact, enhancement)Missing: controversies | Show results with:controversies
[11]
Physical principles for scalable neural recording - PMC
We outline the physical principles governing brain activity mapping using optical, electrical, magnetic resonance, and molecular modalities of neural recording.
[12]
Principles of electrophysiology: an overview - PubMed
This overview gives brief accounts of the mechanism of nerve excitation, receptor/channel functions, cable properties of neurons, and voltage clamp and patch ...Missing: neural | Show results with:neural
[13]
Brain-computer interfaces: a powerful tool for scientific inquiry - NIH
Brain-computer interfaces (BCIs) are devices that record from the nervous system, provide input directly to the nervous system, or do both.
[14]
The Science and Technology of Non-Invasive Neuromodulation
Today's broad range of non-invasive neuromodulatory devices includes electroconvulsive therapy (ECT), transcranial electrical stimulation (TES), transcranial ...
[15]
Neurobiotechnology: A Perspective - PMC - NIH
The Department of Biotechnology launched a program on “Neuroscience” with an aim to support the R&D activities for understanding the brain function.
[16]
Neurotechnology - an overview | ScienceDirect Topics
Neurotechnology is defined as a range of medical devices designed to restore or augment human functions by interfacing with the nervous system, including ...
[17]
The Origins of Brain Stimulation - Brainclinics
Records of electrical stimulation of the brain date back to the early civilizations. Pliny The Elder and Galen of Pergamum described the use of living torpedo ...
[18]
The Long Journey from Animal Electricity to the Discovery of Ion ...
This retrospective begins with Galvani's experiments on frogs at the end of the 18th century and his discovery of 'animal electricity'.
[19]
History of electromyography and nerve conduction studies - PubMed
In 1771, Galvani showed that electrical stimulation of animal muscle tissue produced contraction and, thereby, the concept of animal electricity was born. In ...
[20]
Brief history of electrical cortical stimulation: A journey in time from ...
Animal experiments in the 19th-century to study the brain and to optimize the procedure: Rolando (1809) reported on motor induction, Fritsch and Hitzig (ca. ...
[21]
From Ancient Mysteries to Modern Science: The Story of EEG!
Building upon the foundational work of Galvani and Volta, the mid-19th century saw significant advancements in understanding the electrical nature of nerve ...
[22]
Origin and Evolution of Deep Brain Stimulation - Frontiers
Aug 17, 2011 · In 1883 the Italo-Argentine surgeon Alberto Alberti (1856–1913) conducted an experiment lasting more than 8 months of cerebral stimulation in a ...
[23]
Hans Berger (1873–1941): the German psychiatrist who recorded ...
Oct 22, 2024 · In 1924, at the University Hospital of Jena, Hans Berger first recorded an electrical brain signal in humans. This discovery revolutionized ...
[24]
Neurophysiology and neural engineering: a review - PMC
By the mid-twentieth century, electrical stimulation of the nervous system had seen a resurgence and it had become an accepted clinical modality for pain ...
[25]
Appendix 6. A Brief History of EEG - NCBI - NIH
Hans Berger (1873–1941), a German psychiatrist, recorded the first human EEGs in 1924. In 1934, Fisher and Lowenback first demonstrated epileptiform spikes. In ...Missing: 1900-2000 | Show results with:1900-2000
[26]
Stimulation of the human cortex and the experience of pain: Wilder ...
Oct 27, 2011 · Wilder Graves Penfield and his colleagues were the first to use direct cortical stimulation for intraoperative cortical functional mapping in ...Abstract · Introduction · Results · DiscussionMissing: milestones | Show results with:milestones
[27]
The Montreal procedure: The legacy of the great Wilder Penfield
Penfield mapped the human cortex using electrical stimulation while the patient was awake. The Montreal procedure was the foundation of the modern temporal ...Missing: milestones | Show results with:milestones
[28]
Penfield – A great explorer of psyche-soma-neuroscience - PMC
He also discovered that stimulating parts of the cortex could evoke vivid and specific memories including sounds and smells. Epilepsy arising in the temporal ...Missing: milestones | Show results with:milestones
[29]
The Emergence of Single Neurons in Clinical Neurology - PMC
Single unit recordings in humans have been performed since the mid 1950s (Ward and Thomas, 1955; Rayport and Waller, 1967; Marg and Adams, 1967; Rayport et al., ...
[30]
Brief History of Neurotechnology
1938 Isidor Isaac Rabi first detects the phenomenon of nuclear magnetic resonance (NMR), the underlying principles used in MRI, in a beam of lithium chloride.
[31]
The beginning of intracellular recording in spinal neurons
Intracellular (IC) recording of action potentials in neurons of the vertebrate central nervous system (CNS) was first reported by John Eccles and two colleagues ...
[32]
The Missing Manuscript of Dr. Jose Delgado's Radio Controlled Bulls
Dr. Jose Delgado's 1960s famous experiments on the neural correlates of aggression in which he stopped bulls in mid-charge by electrically stimulating basal ...
[33]
A tribute to Jose M.R. Delgado (1915–2011): The pioneer of electric ...
Delgado pioneered the brain electrode implantation in order to electrically stimulate specific brain areas for treatment epilepsy and of different types of ...
[34]
Origin and Evolution of Deep Brain Stimulation - PMC
Aug 18, 2011 · In mid-twentieth century the advent of stereotactic procedures has allowed the drift from lesional to stimulating technique of deep nuclei of ...
[35]
Deep brain stimulation between 1947 and 1987: the untold story in
Deep brain stimulation was first used in the treatment of movement disorders and was subsequently used in the treatment of psychiatric and behavioral disorders.
[36]
The combination of brain-computer interfaces and artificial intelligence
The Brain Gate group conducted the first human trial of a motor BCI starting in June 2004, which recorded signals from a Blackrock 96-channel MEA implanted ...
[37]
BrainGate Publication Timelines
BrainGate Publication Timelines · 2004. BrainGate clinical trial starts (NCT00912041) at participants' homes · Jul 2006. iBCI control of computer cursor, TV, ...
[38]
Science & Tech Spotlight: Brain-Computer Interfaces | U.S. GAO
Sep 8, 2022 · BCI research has increased significantly in the 21st century resulting in the publication of thousands of research papers. According to one ...Missing: milestones | Show results with:milestones
[39]
NESD: Neural Engineering System Design - DARPA
The Neural Engineering System Design (NESD) program seeks to develop high-resolution neurotechnology capable of mitigating the effects of injury and disease.Missing: century | Show results with:century
[40]
N3: Next-Generation Nonsurgical Neurotechnology - DARPA
N3 aims to develop non-surgical, high-performance brain-machine interfaces, reading/writing to 16 channels within 16mm of neural tissue, without surgery.Missing: engineering century
[41]
Neuralink Business Breakdown & Founding Story - Contrary Research
Neuralink was founded in 2016 by Elon Musk. Musk reportedly met with over 1K potential candidates before deciding on the founding team of Neuralink.
[42]
What Is Neuralink? What We Know So Far. - Built In
Aug 7, 2025 · Neuralink is a neurotechnology company founded by Elon Musk in 2016 that's developed a brain-computer interface (BCI) device called the N1 ...What Will Neuralink Do? · Notable Neuralink... · Neuralink Founding (june...<|separator|>
[43]
Neurotechnology Brain Computer Interface Market Size and Share
Jun 22, 2025 · The neurotechnology brain computer interface market is valued at USD 1.16 billion in 2025 and is forecast to advance at a 15.32% CAGR, which would lift ...
[44]
Brain-computer interfaces face a critical test | MIT Technology Review
Apr 1, 2025 · About 25 clinical trials of BCI implants are currently underway. And this year MIT Technology Review readers have selected these brain ...Missing: key milestones
[45]
Neuroanatomy, Neuron Action Potential - StatPearls - NCBI Bookshelf
Neurons are electrically excitable, reacting to input via the production of electrical impulses, propagated as action potentials throughout the cell and its ...
[46]
The Hodgkin-Huxley theory of the action potential - Nature
Thus, the H-H model links the microscopic level of ion channels to the macroscopic level of currents and action potentials. The model could reproduce and ...
[47]
Action potentials and synapses - Queensland Brain Institute
An action potential travels the length of the axon and causes release of neurotransmitter into the synapse. The action potential and consequent transmitter ...Missing: peer- | Show results with:peer-
[48]
A theory of synaptic transmission | eLife
Dec 31, 2021 · Here, we present an analytic theory of the action-potential-triggered neurotransmitter release at the chemical synapse.
[49]
Translational opportunities and challenges of invasive electrodes for ...
Apr 20, 2023 · In this Review, we discuss concepts and systems for clinically relevant electrophysiology, and summarize the characteristics of neural probes ...Missing: review | Show results with:review
[50]
Hydrogels for next generation neural interfaces - Nature
Jun 12, 2024 · In this review, we first examine the inherent obstacles that persist in existing neural interface technologies, then highlight the noteworthy ...
[51]
A Review of Organic and Inorganic Biomaterials for Neural Interfaces
Microwire electrodes (Figure 1f) are mainly made of conducting metal wires, such as platinum, gold, iridium, stainless steel, and tungsten. Neural recording ...
[52]
Electrode materials for brain–machine interface: A review - Wu
Aug 11, 2021 · In addition, it can dramatically improve the biocompatibility of the interface by developing neural probes with subcellular structures.Abstract · TISSUE RESPONSE TO THE... · MATERIALS FOR... · CONCLUSION...
[53]
Neuron devices: emerging prospects in neural interfaces and ...
Dec 7, 2022 · The main part of the review is divided into two sections, providing an overview of recently developed neuron interface devices for recording ...
[54]
Wireless and battery-free technologies for neuroengineering - Nature
Mar 8, 2021 · In this Review Article, we discuss recent progress in the development of miniaturized and ultralightweight devices as neuroengineering platforms ...
[55]
Signal Generation, Acquisition, and Processing in Brain Machine ...
... data processing (Boniface, 1998). The first theory on how the ... A review on directional information in neural signals for brain-machine interfaces.
[56]
Brain Computer Interfaces, a Review - PMC - PubMed Central
According to the input data processing modality, BCI systems can be ... A review on directional information in neural signals for brain-machine interfaces.
[57]
https://ieeexplore.ieee.org/document/6200523/
[58]
EEG-based brain-computer interface enables real-time robotic hand ...
Jun 30, 2025 · ... neural signals has not yet been demonstrated. To bridge this ... Data processing and visualization was conducted using MNE-Python (1.9.
[59]
Technical survey of end-to-end signal processing in BCIs using ...
Oct 15, 2024 · This paper presents a survey of system architectures and algorithms for end-to-end signal processing pipelines of neural activity on the hardware of such ...
[60]
Review Signal acquisition of brain–computer interfaces: A medical ...
BCIs are increasingly leveraging AI's sophisticated algorithms to discern nuanced patterns in the brain's electrical activity, thereby augmenting the ...
[61]
Modulating Brain Activity with Invasive Brain–Computer Interface - NIH
Jan 12, 2023 · We review the history and recent advances in invasive BCI, particularly through studies using neural signals for controlling external devices on one hand, and ...
[62]
Invasive Brain-Computer Interfaces: A Critical Assessment of ...
Jul 19, 2024 · Invasive brain-computer interfaces (BCIs) are gaining attention for their transformative potential in human-machine interaction.
[63]
DBS Outcomes | Brain Institute - OHSU
Improved movement: One study found that patient motor scores improved 53% after two years with DBS, compared to improving 4% among patients taking medicine.Missing: risks | Show results with:risks
[64]
Efficacy and Safety of Deep Brain Stimulation in the Treatment of ...
Oct 22, 2018 · Overall, DBS was superior to BMT at improving impairment/disability, QoL, and reducing medication doses, but these benefits need to be weighed ...
[65]
Risks of common complications in deep brain stimulation surgery
Nov 15, 2013 · The main object of this study was to assess the incidence of various surgical complications occurring both during and after DBS device implantation.
[66]
Deep brain stimulation - Mayo Clinic
Sep 19, 2023 · Deep brain stimulation is generally considered to be low risk. But any type of surgery has the risk of complications. Also, brain stimulation ...
[67]
Utah Array, Electrodes | Products - Blackrock Neurotech
With its high-channel count, superior signal-to-noise ratio, and exceptional quality, the Utah Array powers the most ambitious neuroscience research.
[68]
How the Utah Array is advancing BCI science
Oct 31, 2022 · In clinical studies, it has been successfully surgically implanted in the brain tissue of patients with paralysis for up to eight years (and ...
[69]
Long-term performance of intracortical microelectrode arrays in 14 ...
Jul 2, 2025 · On average, arrays successfully recorded neural spiking waveforms on 35.6% of electrodes, with only a 7% decline over the study enrollment period.
[70]
Utah Array Characterization and Histological Analysis of a Multi ...
The Utah array is widely used in both clinical studies and neuroscience. It has a strong track record of safety. However, it is also known that implanted ...
[71]
BCIs in 2025: Trials, Progress, and Challenges - Andersen
Jul 20, 2025 · What brain-computer interfaces can and can't do in 2025, based on recent clinical trials, company updates, and use cases.Missing: 2000-2025 | Show results with:2000-2025
[72]
Neuralink Updates
We're excited to announce the launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm. Keep ...Datarepo - Neuralink's... · Neuralink raises $650 million... · A Year of TelepathyMissing: invasive | Show results with:invasive
[73]
Explant Analysis of Utah Electrode Arrays Implanted in Human ...
One recent study examining brain tissue from a human patient implanted with a Utah microelectrode array for 7 months found a substantial degree of tissue damage ...
[74]
Intravascular delivery of an ultraflexible neural electrode array for ...
Nov 1, 2024 · For example, Utah arrays have been extensively used for movement restoration in BMIs, enabling dexterous control of external devices based on ...
[75]
Opportunities and obstacles in non-invasive brain stimulation - PMC
Mar 18, 2024 · Non-invasive brain stimulation (NIBS) is a complex and multifaceted approach to modulating brain activity and holds the potential for broad accessibility.
[76]
Wireless EEG: A survey of systems and studies - ScienceDirect.com
Apr 1, 2023 · Electroencephalography (abbreviated EEG) is a brain monitoring modality with an almost 100-year history of human application (Berger, 1929), and ...
[77]
Electroencephalography (EEG) Technology Applications and ... - MDPI
EEG sensors typically measure the varying electrical signals created by the activity of large groups of neurons near the surface of the brain over a period of ...
[78]
Recent applications of EEG-based brain-computer-interface in the ...
Mar 24, 2025 · First, during the signal acquisition phase, the BCI systems capture raw neural signals ... data processing, algorithm optimization, and ...
[79]
A Brief History of Transcranial Magnetic Stimulation - Psychiatry Online
Mar 1, 2023 · TMS has been best studied for the treatment of depression; in one meta-analysis, the odds ratio of treatment response was 3.17 with left ...
[80]
Transcranial magnetic stimulation - Mayo Clinic
Apr 7, 2023 · Transcranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of major depression.
[81]
Transcranial magnetic stimulation: A review of its evolution and ...
Cognitive impairment has been researched the most in this population and evidence so far suggests that TMS may, in fact, have therapeutic benefits.[56] However, ...
[82]
A review of transcranial direct current stimulation (tDCS) for the ... - NIH
May 7, 2019 · A growing body of evidence suggests that tDCS can elicit antidepressant effects. Though tDCS-related clinical response obtained using ...
[83]
Immediate and long-term efficacy of transcranial direct current ...
Aug 25, 2024 · Overall, the results of meta-analysis indicated that tDCS had a high effect in improving specific symptoms (SMD = −0.73, 95% CI: −1.09 to −0.37) ...
[84]
Transcranial Electrical Stimulation in Treatment of Depression
Jun 18, 2025 · In this systematic review and meta-analysis, we found that tDCS combined with medication was associated with reduced depressive symptoms among ...
[85]
Quantitative Review Finds No Evidence of Cognitive Effects in ...
Our quantitative review does not support the idea that tDCS generates a reliable effect on cognition in healthy adults.
[86]
A Systematic Review of the Available Evidence - PubMed
Objectives: Transcranial direct current stimulation (tDCS) is gaining growing importance in the treatment of neurological and psychiatric disorders and is ...
[87]
fMRI Brain-Computer Interface: A Tool for Neuroscientific Research ...
However, major disadvantages of fMRI-BCI are its high cost and complexity of development and usage. With the wide-spread use of MRI systems in the clinics ...
[88]
Brain-computer interface using fMRI: spatial navigation by thoughts
Aug 5, 2025 · ... Their main disadvantage is lack of portability, cost and challenging data analysis. Implementation of the fMRI is also uncomfortable for the ...
[89]
BRAIN-funded researchers improve noninvasive brain-computer ...
Nov 7, 2024 · Researchers integrate transcranial focused ultrasound with brain-computer interface (BCI) to precisely target parts of the brain and enhance BCI performance.
[90]
Noninvasive Electrical Stimulation Neuromodulation and Digital ...
May 23, 2023 · We review the research progress on noninvasive neural regulatory systems through system design and theoretical guidance.
[91]
The use of chemogenetics in behavioural neuroscience: receptor ...
Chemogenetic receptors are used to selectively modulate the activity of defined neuronal populations, primarily through a systemic drug injection.
[92]
Chemogenetics for cell-type-specific modulation of signalling and ...
Dec 14, 2023 · Chemogenetics is an approach for engineering proteins to enable their modulation by otherwise inert small molecules.Missing: neurotechnology | Show results with:neurotechnology
[93]
Research trends in chemogenetics for neuroscience in recent 14 years
Oct 6, 2023 · Chemogenetic techniques are a method capable of selectively targeting and manipulating cellular activity by activating or inhibiting a specific ...Missing: neurotechnology | Show results with:neurotechnology<|separator|>
[94]
The pharmacology of neuroplasticity induced by non-invasive brain ...
Plasticity induced by NIBS can be modulated by pharmacological interventions, targeting ion channels, or neurotransmitters.
[95]
Combined effects of pharmacological interventions and intermittent ...
Jul 26, 2024 · (2022). Efficacy of adjunctive D-cycloserine to intermittent theta-burst stimulation for major depressive disorder: a randomized clinical trial.
[96]
Neurotechnology and Noninvasive Neuromodulation: Case Study ...
Nov 13, 2023 · This case study was developed as one of a set of three studies, focusing on somewhat mature but rapidly evolving technologies.
[97]
Rapid deep brain chemogenetics: Minimally invasive ... - Science
Jul 31, 2025 · Using our sono-chemogenetics approach, we demonstrated minimally invasive, genetically targeted deep brain neuromodulation at a depth of 9 mm in ...
[98]
Quantitative systems pharmacology in neuroscience - PubMed Central
QSP approaches combine experimental and computational methods to understand the pharmacological effects of drugs on biological systems, which provides a ...
[99]
Chemogenetics as a neuromodulatory approach to treating ...
Chemogenetics enables precise, non-invasive, and reversible modulation of neural activity via the activation of engineered receptors.Missing: neurotechnology | Show results with:neurotechnology
[100]
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Aug 31, 2006 · This trial demonstrated the superior efficacy of neurostimulation over best medical management in patients with advanced Parkinson's disease and ...
[101]
Deep brain stimulation for Parkinson's disease: systematic review ...
Aug 17, 2024 · Objective To assess the benefits and harms of deep brain stimulation for Parkinson's disease. Design Systematic review with meta-analysis ...
[102]
Regulatory Overview for Neurological Devices - FDA
Apr 22, 2024 · Several neurological devices such as a deep brain stimulator and an aneurysm treatment device have been approved through humanitarian device ...
[103]
Long-Term Personalized Adaptive Deep Brain Stimulation in ...
Sep 22, 2025 · This nonrandomized clinical trial evaluates the use of adaptive deep brain stimulation in Parkinson disease.
[104]
A Horizon Scan of Neurotechnology Innovations - PMC
May 21, 2025 · Neurotechnology, Defined as enabling a direct connection of technical components with the nervous system ; Condition(s), Mental health: anxiety; ...Missing: definition | Show results with:definition
[105]
Brain-computer interface advance allows fast, accurate typing by ...
Feb 21, 2017 · A brain-to-computer hookup can enable people with paralysis to type via direct brain control at the highest speeds and accuracy levels reported to date.
[106]
Fully Implanted Brain–Computer Interface in a Locked-In Patient ...
Nov 12, 2016 · We report on a communication system that involves a totally implantable brain–computer interface for home use by a locked-in patient with ALS.
[107]
Brain-computer interface helps paralyzed man speak - NIH
Sep 10, 2024 · Brain-computer interfaces can help people with paralysis to communicate by decoding neural signals into words.
[108]
https://med.stanford.edu/news/all-news/2025/10/eye-prosthesis.html
[109]
Development of visual Neuroprostheses: trends and challenges
Aug 13, 2018 · Visual prostheses are implantable medical devices that are able to provide some degree of vision to individuals who are blind.
[110]
Neural Prostheses and Brain Plasticity - PMC - PubMed Central - NIH
We have used the cochlear implant as a case study to highlight the role of brain plasticity in the efficacy of modern neural prostheses.Missing: vision | Show results with:vision
[111]
Neuralink — Pioneering Brain Computer Interfaces
Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.Updates · Careers · Technology · Clinical Trials
[112]
Neuralink's brain-computer interfaces: medical innovations and ...
Mar 23, 2025 · Concerning brain-computer interface (BCI), the first intervention on a human patient dates back to 1998. In this case, brain stimuli ...
[113]
Brain computer interface to enhance episodic memory in human ...
We developed a brain computer interface (BCI) to test the ability of such pre-stimulus activity to modulate subsequent memory encoding.
[114]
Brain–computer interfaces: the innovative key to unlocking ...
Aug 14, 2024 · Our comprehensive analysis presents BCI technology as an innovative key to unlocking neurological disorders, offering a transformative approach ...
[115]
TNT: Targeted Neuroplasticity Training - DARPA
The Targeted Neuroplasticity Training (TNT) program supports improved, accelerated training of military personnel in multifaceted and complex tasks.
[116]
Elon Musk's Neuralink has put in its first human brain implant - NPR
Jan 30, 2024 · Elon Musk says his ambitious plan to let humans wirelessly connect their brains with phones and other devices has taken a new step.Missing: cognitive | Show results with:cognitive
[117]
DARPA-funded efforts in the development of novel brain–computer ...
Apr 15, 2015 · DARPA has funded innovative scientific research and technology developments in the field of brain–computer interfaces (BCI) since the 1970s.
[118]
Military Applications of Invasive Brain Stimulation
Jun 29, 2017 · The RAM program was created by DARPA with a goal of developing an implantable device that can be used to treat memory problems in patients with ...<|separator|>
[119]
[PDF] Brain-Computer Interfaces: U.S. Military Applications and ... - RAND
Jan 7, 2020 · Noninvasive transcranial direct currents can be used to treat depression and strokes, to increase focus and attention, to shorten training time, ...
[120]
SUBNETS: Systems-Based Neurotechnology for Emerging Therapies
SUBNETS aims to improve force health by using neurotechnology for precise treatments of neuropsychiatric illnesses, using an implanted, closed-loop system.Missing: enhancement | Show results with:enhancement
[121]
Neurotechnology Market Size, Share & Industry Forecast, 2025-2030
Jun 11, 2025 · The neurotechnology market features moderate concentration: with Medtronic, Abbott, and Boston Scientific leading through diversified device ...
[122]
Neurotechnology Market Size to Surpass USD 52.86 Billion by 2034 ...
Jul 7, 2025 · The global neurotechnology market is set to soar from USD 15.30 billion in 2024 to an impressive USD 52.86 billion by 2034, growing at a CAGR of 13.19%.Missing: commercial | Show results with:commercial
[123]
Neurotech consumer market atlas - How the sector is making moves ...
Jun 16, 2025 · Dedicated consumer neurotech firms now account for 60% of the global neurotechnology landscape, with consumer firms outnumbering medical ...
[124]
Neurotechnology is here. What does that mean for children?
Sep 27, 2024 · Convergence with artificial intelligence (AI), nanotechnology and other technologies is rapidly transforming the field of neurotechnology, ...
[125]
Top 5 Trends in Neuroscience You Need to Know in 2025 - qmenta
Jan 25, 2024 · 1. Neuroplasticity & Brain Health · 2. Evolving MRI Machines · 3. Scaling Up Digital Brain Models · 4. AI in the Neuroradiology Clinic · 5. A ...
[126]
Neurotechnology: A New Frontier for Prosperity and Security ... - GPPi
Mar 27, 2025 · Neurotechnology is already flourishing in the medical sector. It enables established instruments that help diagnose and treat certain ...<|control11|><|separator|>
[127]
Silicon Synapses: The Bold Frontier of Brain–Computer Integration
Aug 5, 2025 · The starpower of Elon Musk and Neuralink has turned the spotlight on brain–computer interface (BCI) technology, which is showing glimpses of its ...
[128]
Brain-computer interfaces are closer than you think
Aug 13, 2025 · Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.
[129]
There's Neuralink—and There's the Mind-Reading Company That ...
Jul 21, 2025 · Unlike Elon Musk's brain-computer interface, Synchron's doesn't require open-skull surgery, and it has an OpenAI chatbot baked in.Missing: BrainGate | Show results with:BrainGate
[130]
The top BCI stories of 2025 so far - MassDevice
Oct 3, 2025 · The Synchron Stentrode BCI implant senses motor signals from inside the brain's superior sagittal sinus. [Image courtesy of Synchron].Missing: BrainGate | Show results with:BrainGate
[131]
The state of clinical trials of implantable brain–computer interfaces
Sep 20, 2024 · As of December 2023, the most recent electrode to enter clinical trials is the EVA Stentrode by Synchron (Brooklyn, NY, USA), with implantation ...
[132]
University of Michigan team leads first in-human recording with new ...
Jun 1, 2025 · A research team at University of Michigan completed the first in-human recording from a novel, wireless brain-computer interface.
[133]
Brain-computer interface study wins a top national clinical research ...
Apr 16, 2025 · The new BCI technology is being developed to restore communication for people who can't speak due to paralysis or neurological conditions like ...
[134]
Study of promising speech-enabling interface offers hope for ...
Aug 15, 2025 · Stanford Medicine scientists have developed a brain-computer interface that detects inner speech from speech-impaired patients, in a step ...
[135]
Brain–computer interfaces in 2023–2024 - Chen - Wiley Online Library
Mar 31, 2025 · As of 2023–2024, BCIs have achieved breakthroughs across three domains: therapeutic management of linguistic/motor deficits, mental navigation ...
[136]
Outlook for Noninvasive Brain-Computer Interfaces for AI
Sep 21, 2025 · These results have advanced rapidly in 2023–2025 with new deep-learning and self-supervised methods. ... breakthroughs in decoding continuous ...
[137]
Advances in Wearable High Density fNIRS and Utility for BCI
fNIRS is a non-invasive neuroimaging sensor for BCI. Advances include signal processing and a wearable high-density system to improve BCI accuracy.Missing: advancements | Show results with:advancements
[138]
Application and future directions of brain-computer interfaces in ...
Sep 14, 2025 · Integrating signals like EEG, EOG, and fNIRS helps researchers understand user intent and cognitive states. A multimodal neuroimaging system ...
[139]
Recent Advances in Hybrid Brain-Computer Interface Systems
Non-invasive brain imaging technique that uses light with a wavelength range of 600 to 1000 nm is called NIRS. It is used to measure the hemodynamic ...
[140]
Neurotechnology Market Size to Hit USD 52.86 Billion by 2034
The global neurotechnology market size is calculated at USD 17.32 billion in 2025 and is forecasted to reach around USD 52.86 billion by 2034, ...
[141]
Neuralink raises $650m to widen use of brain implants
Jun 5, 2025 · Brain-computer interface firm Neuralink has completed a $650m financing that it says will help to "bring our technology to more people"
[142]
From lab to life: Blackrock Neurotech is leading the BCI breakthroughs
Aug 21, 2025 · Axon-R launch (May 2025): Blackrock partnered with Cognixion to distribute a non-invasive, AR-enabled BCI headset for research, broadening ...
[143]
Which VCs are funding BCI technology? - Quick Market Pitch
Precision Neuroscience, $155M total funding, Various institutional investors ; Blackrock Neurotech, $200M (2024), Tether ; Synchron, $145M total funding, ARCH ...
[144]
China's Brain Implant Startups Take On Musk's Neuralink in New ...
Sep 18, 2025 · Venture funding for the sector in 2025 has already more than doubled from 2024 levels, raising at least 1.1 billion yuan including 350 million ...
[145]
Ethical Imperatives in the Commercialization of Brain-Computer ...
Oct 10, 2025 · The FDA classifies most implantable BCIs as Class III devices, requiring rigorous premarket approval focused on safety and efficacy, but current ...
[146]
Brain-Computer Interfaces Market Latest Trends and Insights 2025 -
Aug 8, 2025 · Neuralink, Synchron, and Precision Neuroscience have made FDA-approved progress with human BCI implants. ○ BCIs are being used to restore ...
[147]
FDA Approves Layer 7-T BCI | Precision Neuroscience
Aug 13, 2025 · Precision Neuroscience FDA approval of Layer 7-T brain-computer interface boosts BCI trials 2025 with high-resolution, minimally invasive ...Missing: EU | Show results with:EU
[148]
Wired for the future - Centre for Future Generations
Sep 19, 2025 · Game-changing developments are taking place in the emerging field of neurotechnology, with ever growing levels of ambition. The recent ...
[149]
Regulating neural data processing in the age of BCIs
Mar 28, 2025 · The IBC ethics report dedicated a special section on BCIs and raised data risks under the notion of “mental privacy,” summarizing “mind reading” ...
[150]
Mental privacy: navigating risks, rights and regulation
Jun 25, 2025 · Rapid advances in neurotechnology are eroding the boundary between mental activity and data, creating urgent risks for mental privacy.
[151]
The Rise of Neurotech and the Risks for Our Brain Data - New America
BCI technologies face unique cybersecurity threats, as stolen neural data could not only compromise personal privacy but also exacerbate risks related to ...
[152]
Neurotechnology: How we balance opportunity with security
Oct 7, 2025 · Neurotechnology is advancing rapidly, from medical implants to consumer brain-computer interfaces, bringing immense promise but also ...
[153]
Brainjacking in deep brain stimulation and autonomy - PMC
'Brainjacking' refers to the exercise of unauthorized control of another's electronic brain implant. Whilst the possibility of hacking a Brain–Computer ...<|separator|>
[154]
Impact of neural cyberattacks on a realistic neuronal topology from ...
Jan 25, 2024 · However, these initiatives present vulnerabilities in their designs that cyberattackers can exploit to cause brain damage. Specifically, the ...
[155]
The Aftermath of Abandoned Neurotech: Ethical and Regulatory ...
May 8, 2025 · This abandonment raises several risks, including medical complications, data security vulnerabilities, and unmet patient expectations due to ...
[156]
Ethical Challenges of Risk, Informed Consent, and Posttrial ...
Second, implanted device hardware poses risks, including infection, malfunction, erosion, and lead migration or fracture, which may require additional surgery ...
[157]
Legal aspects of unwanted device explantations - ScienceDirect.com
Explantation requires free and informed consent that can be withheld at any time. •. Calls for novel human rights are examined but ultimately dismissed. •.
[158]
Q&A: Ethical decision-making around neurotechnology treatments
Sep 17, 2024 · Cabrera: Key ethical concerns are related to informed consent. The use of advanced neurotechnologies is a value-laden, preference-sensitive ...Missing: controversies | Show results with:controversies
[159]
Mind the gap: bridging ethical considerations and regulatory ...
Jul 22, 2025 · This manuscript explores the ethical dimensions of implantable BCIs (iBCIs), focusing on the central role of Institutional Review Boards (IRBs) in the United ...
[160]
High performance communication by people with paralysis using an ...
Feb 21, 2017 · Brain-computer interfaces (BCIs) have the potential to restore communication for people with tetraplegia and anarthria by translating neural ...
[161]
Brain-computer interface restores natural speech after paralysis - NIH
Apr 29, 2025 · Scientists have been developing brain-computer interfaces, or BCIs, that can translate brain activity into written or audible words to restore communication.Missing: studies | Show results with:studies
[162]
Ethical gaps in closed-loop neurotechnology: a scoping review - PMC
Aug 8, 2025 · These precision medicine interventions optimize therapeutic outcomes while minimizing risks and adverse effects, offering substantial ...
[163]
Qualitative studies involving users of clinical neurotechnology
Aug 14, 2024 · Articles were included if they were written in English, published in a peer-reviewed journal, and reported original research of empirical ...
[164]
Researcher Views on Changes in Personality, Mood, and Behavior ...
The majority of researchers reported being aware of personality, mood, or behavioral (PMB) changes in recipients of DBS/aDBS.
[165]
Does Personality Change Follow Deep Brain Stimulation ... - Frontiers
Jul 29, 2021 · Though most work has been done on dispositional traits, there is not much evidence that dispositional traits change following DBS.Abstract · Does Personality Change... · Review of Empirical Research
[166]
Neurotechnology ethics and relational agency - PMC
Mar 10, 2021 · In this study, we introduce neurotechnologies and summarize three main areas of neuroethical interest in relation to them: identity, ...Missing: "peer- | Show results with:"peer-
[167]
A meta-analysis of the effects of transcranial direct current ...
Sep 23, 2024 · The results show that active tDCS combined with CT statistically effectively improved WM in healthy older adults compared to the control ...Missing: empirical | Show results with:empirical
[168]
https://doi.org/10.1016/j.neuroimage.2012.11.061
[169]
https://doi.org/10.1056/NEJMoa1107212
[170]
A Taxonomy of Harms Inherent in Cognitive Enhancement - Frontiers
Feb 13, 2017 · Here I will outline one possible way to organize our thinking around the harms of cognitive enhancement, with the aims of clarifying the types ...
[171]
Clinical trial results indicate low rate of adverse events associated ...
Jan 14, 2023 · Clinical trial results indicate low rate of adverse events associated with implanted brain computer interface.
[172]
The Potential Harms of Speculative Neuroethics Research - PMC
Finally, this type of work ultimately risks deterring the adoption of the technology (and/or its survival), which could harm countless future patients and ...Missing: neuroenhancement | Show results with:neuroenhancement
[173]
Interim Safety Profile From the Feasibility Study of the BrainGate ...
The BrainGate Neural Interface system has a safety record comparable with other chronically implanted medical devices. Given rapid recent advances in this ...
[174]
Elon Musk's Neuralink Found Its First Patient — What It Could Cost if ...
Apr 9, 2024 · The Neuralink chip is currently estimated to cost $10,500 in exams, parts and labor. The cost to insurers is expected to push the price up to $ ...
[175]
The costs behind Elon Musk's Neuralink clinical trials
Nov 8, 2023 · Each implant surgery is estimated to cost $10,500 to cover exams, parts and labor, the report said. Insurer costs are expected to be $40,000 per ...
[176]
Brain Implant Cost Analysis - Meegle
The cost can range from $30,000 to over $100,000, depending on the type of implant and associated medical care. Who Can Benefit from Brain Implants? Individuals ...<|separator|>
[177]
Mapping the landscape of equitable access to advanced ...
Geographic, social, political, and economic factors shape access to advanced neurotechnologies, yet little previous research has explored the barriers, ...
[178]
North America Neurotechnology Market Size By Application 2025
Sep 25, 2025 · North America Neurotechnology Market size was valued at USD 9.7 Billion in 2024 and is forecasted to grow at a CAGR of 8.2% from 2026 to 2033, ...<|separator|>
[179]
The functional differentiation of brain–computer interfaces (BCIs ...
Nov 27, 2023 · The primary function of a read-out BCI is to retrieve neural data generated by the brain, assess and analyze brain activity, with the aim of ...
[180]
Factors influencing the social acceptance of brain-computer ...
Oct 30, 2024 · This research examines the roles of learning ability, age, health, social support, and socioeconomic status in BCI acceptance.
[181]
[PDF] Neurotechnology and Children's Rights — Preparing for the Future
25. The existing barriers to access to technology are likely to be reflected in the deployment of neurotechnology with profound differences being seen in the ...
[182]
[PDF] From vision to reality Promises and risks of Brain-Computer Interfaces
Mar 21, 2024 · BCIs could significantly impact professional environments and social life by monitoring brain activity, enhancing performance and productivity, ...
[183]
Unpacking the Neurotechnology Market Trends for 2025
Jul 6, 2025 · Global Neurotechnology Market: Expected to grow significantly from $11.56 billion in 2024 to $29.9 billion by 2035 with a CAGR of 9.03% [^2].
[184]
Neurotech is Changing the Way We Treat Disease and Understand ...
Oct 4, 2024 · The five-year $8.6 million initiative aims to improve equitable access to beneficial neurotechnologies and to mitigate the associated risks in medical and ...
[185]
Premarket Approval (PMA) - FDA
May 16, 2019 · Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.Overview · When A Pma Is Required · Data RequirementsMissing: neural implants
[186]
[PDF] Approval Costs and Innovation in Medical Technologies
Sep 29, 2023 · The PMA process is much longer than the 510(k) process and costs, on average, $75 million (Makower et al., 2010).
[187]
Implanted Brain-Computer Interface (BCI) Devices Considerations
May 20, 2021 · This guidance document provides recommendations for nonclinical testing and study design considerations for Investigational Device Exemptions (IDEs) feasibilityMissing: pharmacological | Show results with:pharmacological
[188]
Neuralink and Brain–Computer Interface—Exciting Times for ... - NIH
Apr 15, 2024 · In 2022, US FDA had rejected Neuralink's application citing concerns regarding how it will be implanted, migration of the wires to other parts ...Missing: challenges | Show results with:challenges
[189]
U.S. regulators rejected Elon Musk's bid to test brain chips in humans
Mar 2, 2023 · Neuralink is hardly alone among brain-implant pioneers in slogging through difficult research and regulatory challenges that can drag on for ...
[190]
Exploring Impediments Imposed by the Medical Device Regulation ...
Sep 5, 2024 · The MDR introduces more detailed requirements for all medical devices in terms of development, quality assurance, and clinical evaluation, as ...
[191]
Mind the Gap: Regulating Neurotechnologies in the Consumer Age
May 27, 2025 · Current Governance of Neurotechnology. The EU Medical Device Regulation's (MDR) scope is dependent upon a device's intended purpose, as stated ...
[192]
Neuralink's FDA Troubles Are Just the Beginning - IEEE Spectrum
Apr 2, 2023 · Despite Musk's characteristically overeager timetable, Neuralink's challenges in gaining FDA approval are only mounting. ... In it, Neuralink must ...
[193]
Medical device regulation: Challenges, innovation and the future
Feb 6, 2025 · The introduction of the EU MDR has elevated regulatory standards for medical devices in Europe through stringent classification rules ...Missing: neurotech | Show results with:neurotech
[194]
Who, If Not the FDA, Should Regulate Implantable Brain-Computer ...
As of now, BCIs for human enhancement remain largely untested and their potential unknown, even at the individual level. How do we then judge (let alone legally ...<|control11|><|separator|>
[195]
Brain computer interface is growing but what are the risks?
Jun 14, 2024 · The integration of BCIs raises serious cybersecurity and privacy concerns, such as brain tapping, misleading stimuli attacks and adversarial ...
[196]
Brain-Computer Interfaces: A New Frontier for Hackers - UMGC
Oct 25, 2021 · The promise of BCIs is impressive, but the technology carries attack opportunities for hackers. It is important to understand the cybersecurity ...
[197]
Brain-computer interfaces in safety and security fields: Risks and ...
Risks and applications of BCIs are studied in safety and security fields. Fatigue detection, safety control, and risk identification categories are linked to ...
[198]
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5138265
[199]
Study offers measures for safeguarding brain implants - Yale News
Jul 23, 2025 · In a new study, researchers with Yale's Digital Ethics Center (DEC) recommend measures that BCI manufacturers and government regulators can ...Missing: concerns 2023-2025
[200]
Brain-computer interfaces could allow soldiers to control weapons ...
Dec 2, 2022 · With training, the soldier could then control weapon systems thousands of miles away using their thoughts alone.
[201]
Battlescape Brain: Engaging Neuroscience in Defense Operations
NeuroS/T can be weaponized to target neurological substrates and mechanisms that affect physiology, cognition, emotions and behaviors.
[202]
China Launches Ambitious Plan to Dominate Brain-Computer ...
Aug 28, 2025 · Seven Chinese government departments unveiled a comprehensive BCI roadmap targeting 2027 breakthroughs and 2030 global leadership.Missing: concerns | Show results with:concerns
[203]
Neurotechnology for National Defense: the U.S. and China
Jul 1, 2021 · China has a clearer articulation of their intent to use brain-computer interfaces (BCIs) for both civilian and military purposes. The goals of ...
[204]
Peace and security in the age of neurotechnologies - UNIDIR
Oct 14, 2025 · The potential militarization of neurotechnologies, however, raises significant international security risks, can have disruptive effects on ...
[205]
Neurotechnology and international security | Politics and the Life ...
H2: China will adopt BCI technologies for commercial and military use before the United States if government structure, brain project and military goals, ...
[206]
From Neuroweapons to 'Neuroshields': Safeguarding Brain Capital ...
Aug 10, 2023 · In this paper, we emphasize the importance of brain capital in optimizing national security. Specifically, we explore the dangerous potential of neuroweapons.